Automatiqc® Medical Writing Technology

Innovative AI, cloud-based application to aid in quick and efficient document authoring

We appreciate the innovative spirit of MMS in enabling us to meet important milestones. Excellent job!
SVP, Research & Development
Biotechnology Sponsor

Free up resource time, improve quality, and bring efficiencies to the medical and regulatory writing process

Automatiqc® is a cloud-based solution that utilizes robotic process automation (RPA), a form of artificial intelligence (AI), to apply the required document formatting and style conventions. This frees up writers to focus on the key messaging, stakeholder alignment, and other key elements  that are most critical to the medical and regulatory writing process.

Additional key benefits of Automatiqc include:

  • Removes the burden of style and formatting from the regulatory or medical writer, saving time for critical data elements
  • Built-in set of rules that can be customized to meet any internal company or external audience document style requirements
  • Compounding efficiencies with document amendments, improving the quality of documents and reduces effort for the review and QC steps in subsequent drafts or document amendments
  • Complementary: processed documents are compatible with other tools, including PleaseReview, Veeva RIM and many others
  • Easy output provided in tracked changes for greater visibility to the writer

With this innovative medical writing technology, Automatiqc users are now able to focus where they can bring the greatest value – to the science of Medical & Regulatory Writing.

Get in touch to request a demo of Automatiqc!

Suggested For You

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development